Home › Research › Down syndrome and Alzheimer's
The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome
Clina JG, Helsel BC, Hartley SL, White DA, Fleming-Batayneh VL, Handen B, Christian B, Head E et al.. Alzheimer's & dementia (Amsterdam, Netherlands), 2026-01-18
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction The incidence of Alzheimer's disease (AD) in Down syndrome (DS) exceeds 90%. Approximately 50% of people with DS have congenital heart disease (CHD). Having CHD increases risk for early-onset AD in populations without DS, but it is unclear if CHD influences AD in DS. Methods Data from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS) were used. Participants with CHD ( n = 82, mean age = 39.9 ± 8.5 years, 97.6% White race) were age- and sex-matched to participants without CHD ( n = 82, mean age = 40.5 ± 8.1 years, 98.8% White race). Cognitive assessments and Centiloid load (CL) (positron emission tomography) were compared by CHD status. Results People with CHD scored lower for visuospatial ability ( β = -3.515, p = 0.022) but had higher CL (29.8 ± 12.8 vs. 39.8 ± 12.8, β = 8.00, p = 0.036) and were projected to hit Aβ positivity at a younger age (37.6 and 42.1 years). Discussion Presence of CHD may influence AD progression in DS. Highlights In adults with Down syndrome (DS), those with congenital heart disease (CHD) had higher amyloid beta and reached the threshold for an amyloid positivity at a younger age than those without CHDNo differences in cognition were seen in the age- and sex-matched sample based on CHD status; however, the average age of the sample may be too young to see cognitive changesCHDs may influence the timing of Alzheimer's disease (AD) in adults with DS.
What this study adds
Evidence grade: Low
The record lists 82 participants. In this matched study, adults with Down syndrome and congenital heart disease had higher amyloid burden and were projected to reach amyloid positivity at a younger age than those without congenital heart disease. Reported effect size: 97.6%; 98.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Clina, J. G., Helsel, B. C., Hartley, S. L., White, D. A., Fleming-Batayneh, V. L., Handen, B., et al. (2026). The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.70257
Vancouver
Clina JG, Helsel BC, Hartley SL, White DA, Fleming-Batayneh VL, Handen B, et al. The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands). 2026. doi:10.1002/dad2.70257. PMID: 41561734.
BibTeX
@article{clina2026-41561734,
author = {Clina, J. G. and Helsel, B. C. and Hartley, S. L. and White, D. A. and Fleming-Batayneh, V. L. and Handen, B. and Christian, B. and Head, E. and others},
title = {{The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2026},
doi = {10.1002/dad2.70257},
pmid = {41561734},
url = {https://doi.org/10.1002/dad2.70257}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results People with CHD scored lower for visuospatial ability ( β = -3.515, p = 0.022) but had higher CL (29.8 ± 12.8 vs. 39.8 ± 12.8, β = 8.00, p = 0.036) and were projected to hit Aβ positivity at a younger age (37.6 and 42.1 years).
Why it matters
In this matched study, adults with Down syndrome and congenital heart disease had higher amyloid burden and were projected to reach amyloid positivity at a younger age than those without congenital heart disease. The authors note the sample may be too young to show cognitive differences, and no treatment, cure or prevention was tested.
Study details
- Participants82
- Effect size97.6%; 98.8%
- Evidence strengthLow
How this study scored 48/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring: journal h-index 86 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 82 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 6.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Lauren T. Ptomey: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41561734) |
| Free to read | 2 / 2 | Free to read |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/dad2.70257
- PubMed: 41561734
- Original source →
- Free full text: Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.